Table 2

Comparison of 11 plasma biomarkers between ARDS cases and controls in the derivation cohort

BiomarkerARDS (n=79)No ARDS (n=318)p Value
RAGE (pg/mL)1886 (956–3298)944 (646–1523) <0.001
PCPIII (ng/mL)3.9 (2.9–5.0)3.5 (2.7–4.8)0.251
BNP (ng/mL)0.4 (0.3–0.7)0.4 (0.3–0.6)0.312
Ang-2 (pg/mL)5880 (4429–7724)4007 (2763–5816) <0.001
IL-8 (pg/mL)15.6 (15.6–57.7)15.6 (15.6–34.9) 0.017
TNF-α (pg/mL)1.0 (0.6–3.0)1.4 (0.6–5.1)0.195
IL-10 (pg/mL)18.2 (9.4–82.4)18.1 (8.1–56.7)0.373
VWF (% control)230 (173–353)270 (198–364) 0.045
SP-D (ng/mL)60.3 (37.2–91.9)53.6 (32.9–78.4)0.061
PAI-1 (ng/mL)118.9 (39.1–248.5)92.3 (50.6–174.5)0.476
CC16 (ng/mL)7.0 (4.2–11.2)5.5 (3.4–8.6) 0.004
  • Data as median (IQR).Ang-2, angiopoietin-2; BNP, brain natriuretic peptide; CC16, club cell-16 protein; IL-8, interleukin 8; IL-10; interleukin 10; PAI-1, plasminogen activator inhibitor-1; PCPIII, procollagen peptide-III; RAGE, receptor for advanced glycation endproducts; SP-D, surfactant protein-D; TNF-α, tumor necrosis factor-α; VWF, von Willebrand factor antigen.